Operating profit before deduction of amortization: Kineta (KA)

Graphic logo of Kineta (KA)

The strategic goal of Kineta, Inc. (KA) is to lead the patent race in disrupting tumor immunity. Current operating profit in cash illustrates progress toward this objective, with the current value standing at . Obstacles remain in the complexities of developing imaging agents for occult cancer cells and the implementation of automated systems for analyzing clinical data arrays.

KA Kineta Bio Operating profit before deduction of amortization (07/04/2022 - 11/10/2026)

Summary analytical data breakdowns for Kineta (KA)

- stock value and consensus price forecast:
Market Chart Kineta Corp|KA - Price Target Chart
- company stock exchange capitalization indicators:
Market Valuation Kineta|KA - Total Company Value
- shareholders' equity book value data:
Accounting Value per Share Kineta|KA - Company Net Assets|Market Capitalization to Book Value Ratio kinetabio.com|KA - Aggregate Company Assets
- debt level and financial liquidity data:
Debt to Equity Ratio Kineta, Inc.|KA - Long-Term Debt to Equity|Current Liabilities to Capital Kineta Inc|KA - Company Total Debt|Debt to Net Assets Kineta|KA - Company Long-Term Liabilities|Amount of Current Liabilities Kineta|Intermediate Coverage Ratio kinetabio.com
- earnings and multiples data:
KA - Net Profit|Expected Net Profit Kineta, Inc.|KA - Price to Earnings Ratio|Future Price to Earnings Multiple kinetabio.com|KA - PEG Multiple|EV/EBITDA Multiple Kineta|KA - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Kineta|KA - Net earnings per share for the last 12 months|Earnings per share growth in annualized terms for the last twelve months kinetabio.com|KA - Earnings per share growth in current year|Earnings growth forecast for next year Kineta, Inc.
Fundamental company valuation:KA, Kineta Corp
Flagship merchandise of Kineta, Inc.

This indicator measures net cash flow from operating activities before depreciation, taxes, and interest, reflecting the business's actual ability to generate cash under current market conditions. For Kineta, Inc. (KA), the cash expression of EBITDA confirms the effectiveness of its patent licensing strategy, which stabilizes the biotech startup's liquidity by offsetting the volatility of operating expenses related to immunotherapy development.

Competitor analysis for Kineta, Inc.

Operating income before deduction of amortization NantKwest (IBRX)|IMCR - Profit before payment of interest, taxes and amortization|januxrx.com (JANX) - Operating profit before deduction of amortization|Arcus Biosciences (RCUS) - Profit before payment of interest, taxes and amortization|Operating profit before deduction of amortization Zymeworks Inc|Operating profit before deduction of amortization TNGX|Operating profit EBITDA Iovance Corp|Profit before payment of interest, taxes and amortization Immatics N.V. (IMTX)|xencor.com - Operating profit before amortization|Profit before payment of interest, taxes and amortization Compass Therapeutics, Inc. CMPX|Replimune Group Inc (REPL) - Profit before interest, taxes and amortization|LYEL: Operating profit before deduction of amortization|Operating profit before depreciation charges Innate Pharma S.A (IPHA)|PYXS (pyxisoncology.com) - Operating profit before deduction of amortization|CGEN: Company profit before taxes, interest and amortization|IOBT (IO Biotech) - Operating profit EBITDA|STRO: Income before deduction of interest, taxes and amortization|Operating profit EBITDA INKT|HOWL - Profit before interest, taxes and amortization|Profit before payment of interest, taxes and amortization Immix Biopharma IMMX|Income before deduction of interest, taxes and amortization ALXO|Cue Biopharma, Inc. - Operating profit EBITDA|PDSB - Operating profit EBITDA|sonnetbio.com (SONN) - Profit before payment of interest, taxes and amortization|Profit before deduction of interest, taxes, depreciation and amortization MAIA (MAIA Bio)|Operating profit before deduction of amortization LIMN|Profit before interest, taxes and amortization Lava Tx LVTX|Profit before payment of interest, taxes and amortization NextCure (NXTC)|Operating profit EBITDA leaptx.com (LPTX)|Operating profit EBITDA INTS (Intensity Therapeutics, Inc.)|Operating income before deduction of amortization Sensei Biotherapeutics Inc (SNSE)|TOVX - Profit before payment of interest, taxes and amortization|GRTS (Gritstone bio, Inc.) - Operating profit before amortization|NEXI: Operating profit EBITDA|Profit before interest, taxes and amortization Turnstone Biologics Corp. (TSBX)|Operating profit before deduction of amortization VCNX|HARP (Harpoon Therapeutics Corp) - Company profit before taxes, interest and amortization